Introduction
============

Ventilator-associated pneumonia (VAP) is believed to be the most commonly acquired infection in the intensive care unit (ICU) and is associated with high morbidity and mortality rates ([@B80]; [@B87]). The incidence of VAP ranges from 10 to 25% of all ICU patients, the VAP-related mortality rate is between 24 and 76%, which is 6--21 times higher in the intubated patients ([@B13]). VAP usually occurs 48--72 h after mechanical ventilation and is related to the increased incidence of multidrug-resistant (MDR) infections, prolonged mechanical ventilation, increased antibiotic usage, and patient stay in the hospital ([@B10]). Although prevention efforts may reduce the frequency of these infections, unfortunately, only a few preventive strategies have been demonstrated to be effective in managing VAP, while many others should be further evaluated in large randomized trials before becoming the clinical recommendations ([@B44]). In addition, it's very challenging to make the correct diagnosis of VAP in the clinical setting in the absence of a gold standard ([@B79]; [@B57]; [@B80]).

A prevention policy aiming to reduce VAP remains an important element of the management for patients admitted to ICUs and requiring mechanical ventilation. The current preventive strategies for VAP are mainly directed at colonization and aspiration modification, such as avoiding intubation ([@B9]), oral care ([@B59]), assessing for early weaning and mobility ([@B5]; [@B38]), and prophylactic probiotics ([@B93]). The empiric treatment strategies of VAP should be informed by the local distribution of pathogens and their antimicrobial susceptibilities, because the pathogens responsible for VAP and the drug-resistance situation are varying from region to region ([@B91]; [@B12]; [@B52]; [@B3]). VAP is commonly caused by *Pseudomonas aeruginosa*, *Klebsiella pneumonia*, and *Acinetobacter baumannii* globally. It is important that the antimicrobial therapy be right in the first time in VAP patients, because the pathogens associated with inappropriate initial therapy are usually antibiotic-resistant strains of these pathogens, so patients at high risk of infection with these organisms initially needed to receive a combination of agents providing a very broad spectrum of coverage ([@B92]; [@B71]). This review aims to summarize the available knowledge on drug prevention and control of VAP, taking profit from the recommendations of several health organization such as the American Thoracic Society with the Infectious Disease Society of America ([@B33]), the Centers for Disease Control and Prevention (CDC) ([@B78]), the European Task Force on VAP ([@B85]), the Society for Healthcare Epidemiology of America, and the Institute for Healthcare Improvement ([@B39]), as well as the recently major guidelines for the management of VAP ([@B33]; [@B80]; [@B83]), and we hope that our clinicians know more about the initial therapies and treatment strategies of VAP, and we can investigate and focus on the management of the disease in future.

Definition and Diagnosis of VAP
===============================

Currently, there is no gold standard and valid definition for VAP, even the most widely used VAP criteria and definitions are neither sensitive nor specific. From 2013, the ventilator-associated event (VAE) was established by CDC based on a novel and multi-tiered algorithm, including definitions for a ventilator-associated condition (VAC), infection-related ventilator-associated complication (IVAC), and possible or probable VAP (PVAP). These definitions were developed in order to better capture infectious and non-infectious events in patients receiving mechanical ventilation ([@B48]). Unfortunately for the bedside practitioner, the new CDC definition for VAP has been found to have a sensitivity as low as 37% with a negative predictive value of only 84%, suggesting that VAE algorithm might not be intended for use in the clinical management of patients. In 2016, CDC reported a module about the definition of VAP is pneumonia that arises at least 48 h after endotracheal intubation ([@B19]). As shown in [Figure 1](#F1){ref-type="fig"}, despite lacking a gold standard definition for VAP, they are still based on a combination of radiographic, laboratory, and clinical findings. Clinical suspicion of VAP in a patient is the initial part of the diagnosis, and the recommended standard diagnostic criteria for VAP is as follows: (i) radiographic (such as new or progressive and persistent infiltrates, consolidation or cavitation); (ii) laboratory evidence (such as blood count of white blood cell not more than 4 or at least 12 × 10^3^ cells/mm^3^); (iii) clinical evidence (such as temperature \<36°C or \>38°C, new onset or increase of purulent aspirates, wheezing, rales, rhonchi, or worsening gas exchange) ([@B23]; [@B80]; [@B83]; [@B54]; [@B89]).
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In addition, microbiologic criteria are also an important element for VAP in a clinical context, such as positive culture results from suctioned sputum, bronchoscopy, blind bronchoalveolar lavage (BAL), or pleural fluid. Although not required to diagnose VAP, serial cultures and microscopic assessments of tracheal aspirate samples during treatment can be useful gauges of the patient's response to antibiotics ([@B50]; [@B20]). VAP can also be divided into early- and late-onset VAP. VAP developing within 4 days of admission are defined as early-onset VAP, which are usually caused by microorganisms sensitive to antibiotics. VAP occurring more than 4 days after admission are defined as late-onset VAP, which are most commonly associated with MDR pathogens and related to higher mortality than early-onset VAP ([@B58]; [@B51]; [@B83]).

Causative Pathogens and Risk Factors of VAP
===========================================

A lot of microbes were detected as a causative agent of VAP, the common pathogens of VAP include Gram-negative bacteria such as *P. aeruginosa*, *Escherichia coli*, *Acinetobacter species*, and *K. pneumoniae*, and Gram-positive bacteria such as *Staphylococcus aureus* ([@B11]; [@B15]). For fungal VAP, because the Candida species are commonly cultured in respiratory samples, it is rarely an etiology of VAP, rarely causes invasive disease, and it is not recommended to use the routine administration of antifungal therapy when Candida species are found in the pulmonary secretions of mechanical ventilation patients ([@B33]). Two groups of risk factors for VAP have been identified, including host-related factors and ventilation-related factors. For example, medical history, gender, age, neurological disorders and comorbidities such as acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), ulcer disease, organ failure, and immunosuppression are particularly important causes of VAP. In addition, ventilation-related factors usually include duration of the mechanical ventilation, reintubation, absence of subglottic secretion drainage, nasogastric tubes, tracheostomy, intracuff pressure of less than 20 cm H~2~O, and prior intravenous antibiotic use within 90 days. The causative pathogens and risk factors for VAP are listed in [Table 1](#T1){ref-type="table"} ([@B40]; [@B33]; [@B24]; [@B73]; [@B80],[@B81]; [@B35]; [@B87]).

###### 

The causative pathogens and risk factors for VAP.

  Type of pathogens   Risk factors                                                                                                                                                                                                                                                                                                                                                                                                                                 
  ------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Bacterium           *Methicillin-sensitive Staphylococcus aureus MRSA Pseudomonas aeruginosa Acinetobacter baumannii Streptococcus pneumoniae Escherichia coli Klebsiella pneumoniae Anaerobic bacteria Legionella ESBL-PE*   Medical history and underlying illness Male Age \> 60 years Prior central nervous system disorder Immunocompromised Acute underlying diseases Emergent surgery Surgical history Organ failure ARDS COPD Burns ECOM Ulcer disease   Peri-operative transfusion of blood products Duration of the mechanical ventilation Reintubation Supine head position in patients receiving enteral nutrition Enteral nutrition Absence of subglottic secretion drainage Intra-hospital transports Continuous sedation, use of paralytic agents Nasogastric tubes Tracheostomy Frequent ventilator circuit changes Intracuff pressure of less than 20 cm H~2~O Prior intravenous antibiotic use within 90 days
  Fungus              *Aspergillus Candida*                                                                                                                                                                                                                                                                                                                                                                                                                        
  Virus               *Influenza Respiratory syncytial virus*                                                                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

VAP, ventilator-associated pneumonia; MRSA, methicillin-resistant Staphylococcal aureus; ESBL-PE, extended-spectrum β-lactamase--producing Enterobacteriaceae; ARDS, acute respiratory distress syndrome; COPD, chronic obstructive pulmonary disease; ECMO, extra-corporeal membrane oxygenation.

Strategies for Prevention of VAP
================================

Multiple international guidelines regarding the prevention of VAP are available, and the current preventive strategies for VAP are mainly directed at colonization and aspiration modification ([Table 2](#T2){ref-type="table"}).

###### 

Strategies for prevention of VAP.

  VAP preventive measures
  -----------------------------------------------------
  minimize ventilator exposure
  intensive oral care
  aspiration of subglottic secretions
  maintain optimal positioning and encourage mobility
  prophylactic probiotics

VAP, ventilator-associated pneumonia.

Minimize Ventilator Exposure
----------------------------

The first choice for lowering VAP risk is minimizing a patient's exposure to mechanical ventilation ([@B37]; [@B7]). The use of non-invasive ventilation approaches is encouraged, such as bi-level positive airway pressure (BiPAP) or continuous positive airway pressure (CPAP). If mechanical ventilation can't be avoided, work to minimize its duration. Ventilator weaning protocols (for example, daily interruption of sedation and coordination with a spontaneous breathing trial) or evidence-based care bundles can be effective in shortening mechanical ventilation duration.

Intensive Oral Care
-------------------

The oral health quickly deteriorates in mechanically ventilated patients, and professional oral hygiene care is believed to help reduce the risk of VAP ([@B77]). The bacterial load presented in the teeth, gums, tongue, and oral mucosa is different between patients with or without treated with antibiotic therapy and mechanical ventilation ([@B82]; [@B75]). Chlorhexidine, a broad-spectrum antiseptic agent, has been shown to reduce the incidence of VAP when used for oral care. [@B97] have suggested that oral decontamination with 2% is more effective in the prevention of VAP and reduction of oropharyngeal colonization compared with 0.2% chlorhexidine. A previous meta-analysis shows that oral care with chlorhexidine might be effective in reducing VAP incidence in the adult population when administered at 2% concentration or 4 times/day ([@B90]). However, [@B69] suggests that administration of chlorhexidine for the prevention of VAP was inconclusive, so further studies are needed to confirm the role of intraoral chlorhexidine in the management of VAP.

Aspiration of Subglottic Secretions
-----------------------------------

The core mechanism in the development of VAP is oropharyngeal secretions accumulate above and below the endotracheal cuff, facilitating the drainage into the lower airways, so the subglottic secretion suctioning seems to be a pivotal way to prevent VAP. A recent meta-analysis of 20 randomized controlled trials (RCTs) performed by [@B49] suggested that subglottic suctioning reduced the risk for VAP by 45% compared to the control group, and subglottic secretion suction was recommended for preventing VAP and for reducing ventilation length, especially in the population at high risk of early-onset VAP.

Maintain Optimal Positioning and Encourage Mobility
---------------------------------------------------

It has been shown that supine intubated patients have a higher risk of aspiration of gastric contents compared to intubated patients in semi-recumbent position (Keeping the head of the bed elevated between 30 and 45 degrees) ([@B84]; [@B64]; [@B18]), suggesting that the semi-recumbent patient position might be an effective and easy method to prevent VAP. In addition, although it seems challenging, early mobility might also be important for intubated patients because it results in more ventilator-free days ([@B7]; [@B94]).

Probiotics
----------

Recently, a new strategy in the fight against VAP is the use of probiotics. It is widely believed that probiotic bacteria can decrease the development of VAP through local and systemic actions that improve intestinal barrier function, increase host cell antimicrobial peptides, regulate the composition of the intestinal flora, and reduce overgrowth of pathogenic bacteria and bacterial translocation ([@B53]; [@B47]; [@B29]; [@B34]). Several studies have also suggested that probiotics can be safe and efficacious in the prevention or amelioration of VAP in ICU patients ([@B22]; [@B56]; [@B67]). We should keep in mind that the side-effects of the probiotics are also existed, such as transfer of antibiotic resistance, toxic effects on the gastrointestinal tract, occurrence of disease sepsis and endocarditis ([@B62]; [@B93]). The incompatible results between studies may be due to differences in patients and clinical situations, the method of probiotic administration, the criteria used in the diagnosis of VAP and the sample size, or the heterogeneity of the probiotic strains used. Therefore, the current opinion for probiotics is believed that although probiotics are usually considered to be safe and well tolerated, while the wide, well-planned, randomized and multicenter studies are required to verify the efficacy of probiotics against VAP before they can be recommended for routine clinical application.

Drug Strategies for Treatment of VAP
====================================

It is important to note that once VAP is considered likely for a patient, the selection of initial empiric antimicrobials may have great variability among clinical scenarios. However, currently, evidence supporting a standardized approach to the exact initial selection of antimicrobials is lacking. Antibiotic resistance has exponentially increased over the last decade, and the isolation of MDR pathogen has been identified as an independent predictor of initial inadequate antibiotic therapy and increased mortality ([@B88]), and the risk of MDR is based on the local ecological data, previous colonization, and previous antibiotic therapy received by the patients. Moreover, there are lots of attempts to control VAP, such as novel antibacterial agents, inhaled antibiotics and monoclonal antibodies. We summarized the reference approaches adapted from recent recommendations or studies for the management of VAP ([@B65]; [@B33]; [@B24]; [@B73]; [@B80]; [@B6]; [@B35]; [@B87]), details were shown in [Table 3](#T3){ref-type="table"}.

###### 

Drug strategies for treatment of VAP.

  Category                  Strategies                                                                                                 Notes
  ------------------------- ---------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------
  Intravenous antibiotics                                                                                                              
  Without risk factors      Piperacillin-tazobactam 4.5 g IV q6h                                                                       --
                            Cefepime 2 g IV q8h                                                                                        --
                            Levofloxacin 750 mg IV daily                                                                               --
  Gram-positive             Vancomycin 15 mg/kg IV q8--12h (consider a loading dose of 25--30 mg/kg × 1 for severe illness)            --
                            Linezolid 600 mg IV q12h                                                                                   --
                            Tedizolid 200 mg oral or IV q24h                                                                           Phase III for HAP and VAP (NCT02019420)
  Gram-negative             Piperacillin-tazobactam 4.5 g IV q6h                                                                       --
                            Cefepime or ceftazidime 2 g IV q8h                                                                         --
                            Ceftolozane--tazobactam 3 g IV q8h                                                                         Phase III trial for VAP, HAP (NCT02070757)
                            Ceftazidime--avibactam 2.5 g IV q8h                                                                        Phase III trial for nosocomial pneumonia including VAP (NCT01808092)
                            Levofloxacin 750 mg IV daily                                                                               --
                            Ciprofloxacin 400 mg IV q8h                                                                                --
                            Imipenem 1g IV q8h                                                                                         --
                            Meropenem 1 g IV q6h                                                                                       --
                            Meropenem--vaborbactam 2 g IV q8h                                                                          Phase III trial for the treatment of HAP/VAP (NCT03006679)
                            Imipenem--relebactam 500 mg/250--125 mg IV q6h                                                             Phase III for VAP, HAP (NCT02452047); Phase III for VAP, HAP (NCT02493764)
                            Aztreonam 2 g IV q8h                                                                                       --
                            Amikacin 15--20 mg/kg IV q24h                                                                              --
                            Gentamicin 5--7 mg/kg IV q24h                                                                              --
                            Tobramycin 5--7 mg/kg IV q24h                                                                              --
                            Plazomicin 15 mg/kg IV q24h                                                                                Phase III for BSI, HAP, VAP (NCT01970371)
                            Colistin 5 mg/kg IV × 1 (loading dose) followed by 2.5 mg × (1.5 × CrCl + 30) IV q12h (maintenance dose)   --
                            Polymyxin B 2.5--3.0 mg/kg/d divided in 2 daily IV doses                                                   --
  Inhaled antibiotics       Colistin                                                                                                   Indetermination
                            Aminoglycosides (such as sisomycin, gentamicin, amikacin, and tobramycin)                                  Indetermination
                                                                                                                                       

IV, intravenous; q, every; VAP, ventilator-associated pneumonia; HAP, hospital-acquired pneumonia.

Antibiotic
----------

The aim is to choose antibiotics that target specific pathogens of VAP as narrowly as possible, this will ensure optimal treatment while minimizing overtreatment and negative outcomes. The current recommendations for initial empiric antibiotic selection urge the clinician to consider local microbiology patterns because the inappropriate initial antibiotic choice is associated with increased mortality ([@B55]; [@B95]; [@B80]). In addition to local antibiograms, patient-specific risk factors should be used to identify patients at risk for MDR organisms who may necessitate coverage of methicillin-resistant *Staphylococcal aureus* (MRSA), extended-spectrum β-lactamase--producing *Enterobacteriaceae* (ESBL-PE), *Pseudomonas species*, *Klebsiella species*, or *A. baumannii* until susceptibilities are available ([@B43]; [@B17]; [@B81]). Antibiotic regimens for VAP are to be treated for a short course (7 or 8 days) according to the recommendation, because the available data suggest there is no significant difference between short-course (7 or 8 days) and long-course (10--15 days) antibiotic regimens in regard to mortality, treatment failure, recurrent pneumonia, or duration of mechanical ventilation ([@B14]). The longer courses may be appropriate in some circumstances where the patient may have a delayed clinical response. When it comes to combination therapy, a meta-analysis was performed by [@B1] to evaluate the role of combination therapy as empiric treatment for VAP, which was included in 41 trials and 7,015 patients, the results suggest that rates of mortality and treatment failure between monotherapy and combination therapy are similar, while the adverse events are found to be slightly higher in the combination group. Meanwhile, it is critical that to regularly monitor the pattern of MDR organisms in ICU in the management of VAP, and effective national- and state-level monitoring of resistance patterns, antibiotic policy, and draft guidelines are needed to maintain the effectiveness of antimicrobials and for better VAP control ([@B24]). In the past decades, lots of new antibiotics against MDR have been approved for the therapeutic intervention of VAP, and other agents are being investigated, such as tedizolid, meropenem--vaborbactam, imipenem--relebactam, ceftolozane--tazobactam, ceftazidime--avibactam, and plazomicin ([@B32]; [@B6]). We believe that these new approved and investigational agents for the treatment of VAP represent promising options to preserve and enhance our antibiotic choices in the future.

Inhaled Antibiotics
-------------------

It was observed in some studies that inhalation antibiotics may have beneficial effect in the clinical cure of VAP ([@B36]; [@B25]; [@B45]; [@B86]; [@B66]). However, other studies showed no statistically significant effect in their primary outcome ([@B42]; [@B70]; [@B46]; [@B60]; [@B16]). A previously published meta-analysis of 6 randomized controlled trials and 6 observational studies performed in VAP shows that the use of inhalation antibiotics is associated with higher rates of clinical cure, while the statistical significance is not reached in the meta-regression analysis ([@B96]). There is a non-significant improvement in clinical cure when using inhalation antibiotics as an adjunctive treatment in VAP besides using systemic antibiotics until now, and more evidence from larger randomized controlled trials (RCTs) is needed to confirm the appropriateness of this adjunctive treatment ([@B72]).

Monoclonal Antibodies
---------------------

At present, the drugs in development for the treatment of VAP can significantly improve the therapeutic options available. The possibility to administer directed therapy with monoclonal antibodies to specific pathogens is an exciting strategy in the fight against widespread resistance of MDR organisms. For example, [@B68] have reported that the full course of panobacumab, an anti-lipopolysaccharide (LPS) immunoglobulin M monoclonal antibody, adjunctive immunotherapy targeting serotype-specific LPS of *P. aeruginosa* O11 may have improved the clinical outcome of patients presenting with nosocomial pneumonia. Different monoclonal antibodies, including panobacumab ([@B41]; [@B26]), KB001 ([@B76]; [@B4]; [@B21]), and MEDI4893 ([@B28], [@B27]), directed against components of *P. aeruginosa* or *S. aureus* are now being studied for nosocomial respiratory infections. However, most of these studies are in very preliminary stages of development, and it is actually impossible to know what their future role in the therapy of VAP will be. The use of certain monoclonal antibodies directed against some specific serotypes of specific pathogens is an interesting approach to try to reduce antimicrobial resistance.

Future Directions
=================

In the coming decade, VAP will continue to be a major infection in the ICU. We anticipate the need for better epidemiologic and diagnostic tools that will inform us about the true incidence of these infections and the impact of specific prevention and treatment strategies. For prevention, a VAP care bundle, nursing care and education are recommended; these strategies have been shown to decrease the health care costs and antimicrobials use, length of ICU stay, and the need of mechanical ventilation therapy ([@B2]; [@B63]; [@B61]; [@B31]). In addition, a recent study has suggested that *N*-acetyl-cysteine (NAC) is safe and effective to prevent and delay the development of VAP ([@B74]). It's also very important to use new diagnostic methods (such as next-generation sequencing technology, phase contrast X-ray imaging, lung ultrasonography ([@B8]), and the electronic nose) and/or new biomarkers (such as phosphatidylinositol 3-kinase regulatory subunit and sarcoplasmic reticulum calcium transporting ATPase) ([@B30]), to find the bacteriology and its frequency of MDR pathogens and to guide more accurate and focused initial antibiotic therapy. Moreover, it is very urgent to develop new drugs for MDR pathogens because of increasing antimicrobial resistance. There will also be further exploration of optimized antibiotic pharmacokinetics (PK) and pharmacodynamics (PD), which will allow us to improve the effectiveness of the treatments of pneumonia caused by MDR organisms as well as to achieve a lower rate of adverse effects. We believe that with focus on VAP epidemiology, diagnostic methods, bacteriology, prevention, and therapy, we will see further improvement in the outcomes of our patients.

Conclusion
==========

Ventilator-associated pneumonia is an important cause of morbidity and mortality in mechanically ventilated patients, and many strategies have been proposed for the prevention and treatment of this disease. Successful prevention of VAP can save on total costs and is possible using a multidisciplinary clinical and administrative approach. In addition, the early appropriate antimicrobial therapy is critical to improving clinical outcomes for patients with VAP. Unfortunately, clinician failure is common, with about 70% of patients receiving inadequate initial empiric therapy for VAP. Some new antibiotics such as tedizolid, meropenem--vaborbactam, imipenem--relebactam, ceftazidime--avibactam, ceftolozane--tazobactam, and plazomicin, are being developed for VAP to combat our increasingly resistant infecting organisms. Meanwhile, some new options and choices for the management of VAP are also being developed, including inhaled antibiotics and monoclonal antibodies. Future studies are necessary to evaluate these therapeutic strategies in the management of VAP. We hope that the present overview contributes to the prevention and control of VAP.
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